- Home
- AGL vs WVE Comparison
AGL vs WVE Comparison
Compare AGL & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- WVE
- Stock Information
- Founded
- AGL 2016
- WVE 2012
- Country
- AGL United States
- WVE Singapore
- Employees
- AGL N/A
- WVE N/A
- Industry
- AGL Managed Health Care
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- WVE Health Care
- Exchange
- AGL Nasdaq
- WVE Nasdaq
- Market Cap
- AGL 1.4B
- WVE 1.7B
- IPO Year
- AGL 2021
- WVE 2015
- Fundamental
- Price
- AGL $4.08
- WVE $7.74
- Analyst Decision
- AGL Hold
- WVE Strong Buy
- Analyst Count
- AGL 18
- WVE 11
- Target Price
- AGL $3.85
- WVE $22.00
- AVG Volume (30 Days)
- AGL 5.6M
- WVE 1.3M
- Earning Date
- AGL 05-06-2025
- WVE 03-04-2025
- Dividend Yield
- AGL N/A
- WVE N/A
- EPS Growth
- AGL N/A
- WVE N/A
- EPS
- AGL N/A
- WVE N/A
- Revenue
- AGL $6,060,530,000.00
- WVE $108,302,000.00
- Revenue This Year
- AGL $2.12
- WVE N/A
- Revenue Next Year
- AGL $13.99
- WVE $33.28
- P/E Ratio
- AGL N/A
- WVE N/A
- Revenue Growth
- AGL 40.41
- WVE N/A
- 52 Week Low
- AGL $1.50
- WVE $4.25
- 52 Week High
- AGL $7.73
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- AGL 51.56
- WVE 31.52
- Support Level
- AGL $4.39
- WVE $9.43
- Resistance Level
- AGL $4.68
- WVE $10.91
- Average True Range (ATR)
- AGL 0.26
- WVE 0.63
- MACD
- AGL -0.03
- WVE -0.18
- Stochastic Oscillator
- AGL 23.31
- WVE 3.21
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.